Tolterodine
- Generic Name
- Tolterodine
- Brand Names
- Detrol, Detrusitol
- Drug Type
- Small Molecule
- Chemical Formula
- C22H31NO
- CAS Number
- 124937-51-5
- Unique Ingredient Identifier
- WHE7A56U7K
- Background
Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.
- Indication
For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
- Associated Conditions
- Urinary Urge Incontinence
MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence.
- Conditions
- Overactive Bladder
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-02-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 118
- Registration Number
- NCT00174798
- Locations
- 🇺🇸
Hudson Valley Urology Center, Kingston, New York, United States
🇺🇸Hudson Valley Urology, Poughkeepsie, New York, United States
🇺🇸Rockhill Medical Plaza, Kansas City, Missouri, United States
Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction
- Conditions
- Urinary Incontinence
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Target Recruit Count
- 830
- Registration Number
- NCT00147654
- Locations
- 🇺🇸
Pfizer Investigational Site, Cheyenne, Wyoming, United States
Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB
- Conditions
- Urinary Incontinence
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT00143377
Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women
- Conditions
- Urinary Incontinence
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT00143481
- Locations
- 🇺🇸
Pfizer Investigational Site, Morgantown, West Virginia, United States
Evaluate Efficacy and Safety Of Tolterodine Extended Release Capsule Compared With Tolterodine Immediate Release Tablet
- Conditions
- Urinary Incontinence
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT00139724
- Locations
- 🇨🇳
Pfizer Investigational Site, Shanghai, China
A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder
- Conditions
- Urinary Incontinence
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT00137397
- Locations
- 🇬🇧
Pfizer Investigational Site, Pl6 8Dh, United Kingdom
Behavior Enhances Drug Reduction of Incontinence (BE-DRI)
- Conditions
- Urinary Incontinence (UI)
- Interventions
- Behavioral: Behavioral training
- First Posted Date
- 2004-08-31
- Last Posted Date
- 2013-06-17
- Lead Sponsor
- Carelon Research
- Target Recruit Count
- 307
- Registration Number
- NCT00090584
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸Oakwood Hospital and Medical Center, Royal Oak, Michigan, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.